Ionis Pharmaceuticals (NASDAQ: IONS) reported Q1 EPS of ($0.93), $0.15 better than the analyst estimate of ($1.08). Revenue for the quarter came in at $132 million versus the consensus estimate of $136.69 million.

GUIDANCE:

Ionis Pharmaceuticals sees FY2025 revenue of $725-750 million, versus the consensus of $653.5 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.